Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a Healthcare stock trading at $8.25 (as of 2026-06-18), with a market capitalization of $146.55M and a trailing P/E of -1.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company developing immune-modulating therapies for immuno-oncology and fibrosis, including lenabasum, an oral CB2-selective activator, and antibody programs (CRB-601 and CRB-602) designed to inhibit TGFß activation in cancer and fibrotic indications. It also advances a CB1 inverse agonist approach for metabolic and fibrotic diseases under development, with related programs supported by a licensing arrangement with Jenrin Discovery, LLC.

Valuation — source: SEC EDGAR (first-party)
Price	$8.25
Market Cap	$146.55M
P/E Ratio	-1.4
EV / EBITDA	-1.4
Price / Book	1.20
DCF Value (model)	$-60.26
DCF Upside vs Price	-830.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-66.9%
Current Ratio	7.92

Valuation vs Sector & Industry
Stock P/E	-1.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-106.8%
vs Industry	-108.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Cormorant Asset Management, LP ($22.02M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Yuval Cohen
Employees	28
Country	US
IPO Date	2014-10-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.